EUCTR2014-001377-14-ES进行中（未招募）不适用
A multicenter, single arm, phase II clinical trial of pimecrolimus administered topically to patients with Stages Ia-IIa mycosis fungoides. - Study PimTo-MF.
Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre0 个研究点开始时间: 2014年5月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological diagnosis of Mycosis Fungoides (Stage IA-IIA) confirmed by previous or current biopsy. If the previous biopsy was inconclusive, a confirmatory biopsy must be obtained before entering the study.
- •Willingness and ability to sign inform consent and sign it up.
- •Functional status according to the Eastern Cooperative Oncology Group (ECOG) of the subject between 0 and 1 at the screening visit.
- •Age ? 18 years.
- •An acceptable organic functional condition defined by certain hematological and biochemical values.
- •Women of childbearing potential must have a pregnancy test negative seven days before inclusion in the study.
- •Patients women and men married to women of childbearing potential must use contraception during the entire period of treatment and for one month afterwards. A non-hormonal contraceptive treatment is also necessary for women who use hormonal measures. Men with female partners of childbearing age or pregnant women, patients must use condoms in sexual intercourse during the treatment period.
- •Breastfeeding women should discontinue nursing prior to treatment initiation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Subjects with a history of other primary malignancies within 5 years prior or concomitant (except in situ cancer, basal cell carcinoma or squamous cell skin carcinoma, adequately treated).
- •Known or suspected hypersensitivity to treatment with tacrolimus or pimecrolimus.
- •No previous wash up of at least 1 month of any previous treatment unless patient is in progressive disease. In that case wash up should be at least 2 weeks.
- •Concurrent treatment for Mycosis Fungoides. Topical or systemic corticosteroids are strictly prohibited. It is not allowed concurrent use of other calcineurin inhibitors.
- •Patient not fully recovered from toxicity/adverse event secondary to any previous treatment.
- •Diagnosis of any serious intercurrent illness or infection at the time of entering the study, which may interfere with the study treatment.
- •Patients who are unable to apply, either by themselves or by their relatives or carers, the study investigational drug in the affected areas.
- •Known contraindication to pimecrolimus or its excipients.
- •Patienst must not have participated in another clinical trial in the 30 days prior to entry into this trial nor have participated in any other study with tacrolimus or pimecrolimus.
- •Diagnosis of active or chronic infection with HIV, HBV or HCV. Absence of any active infection.
- •Psychological, familial, sociological or geographical condition that may impede compliance with the study protocol and follow-up program, these conditions should be discussed with the patient before inclusion in the trial.
研究者
相似试验
进行中（未招募）
不适用
Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GISTEUCTR2005-004837-16-DEovartis Pharma GmbH53
招募中
不适用
A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumorcolorectal cancerJPRN-UMIN000026817PO Epidemiological and Clinical Research Information Network(ECRIN)55
招募中
2 期
A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.bone cancer10040778chondrosarcomaNL-OMON47217eids Universitair Medisch Centrum23
进行中（未招募）
1 期
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsEUCTR2013-005155-32-NLeiden University Medical Center108
进行中（未招募）
1 期
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsConventional chondrosarcomaMyxoid liposarcoma with PIK3CA mutation or PTEN lossMesenchymal or dedifferentiated chondrosarcomaEUCTR2013-005155-32-ESGrupo Español de Investigación en Sarcomas (GEIS)